CTOR — Citius Oncology Balance Sheet
0.000.00%
- $117.87m
- $121.67m
Annual balance sheet for Citius Oncology, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Cash and Short Term Investments | 0 | 0 | 0 |
| Total Inventory | |||
| Prepaid Expenses | |||
| Total Current Assets | 2.69 | 7.73 | 11 |
| Net Intangible Assets | |||
| Total Assets | 42.7 | 47.7 | 84.4 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 5.85 | 21 | 32.7 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Deferred Income Tax | |||
| Total Other Liabilities | |||
| Total Liabilities | 6.42 | 22.2 | 38.2 |
| Non Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Total Equity | 36.3 | 25.5 | 46.1 |
| Total Liabilities & Shareholders' Equity | 42.7 | 47.7 | 84.4 |
| Total Common Shares Outstanding |